About Holy Name Medical Center
List of Clinical Studies |
|
| Multiple Sclerosis | |
| Study Name | Principal Investigator |
 |
|
|
A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment Read more. |
Mary Ann Picone, MD |
|
|
|
Randomized, multi-center, double-blinded, active-controlled study that is primarily designed to assess the Annualized Relapse Rate (ARR) and safety/tolerability of ublituximab/oral placebo (TG-1101; UTX) as compared to teriflunomide/IV placebo in subjects with Relapsing MS. Read more. |
Mary Ann Picone, MD |
|
|
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies Read more. |
Mary Ann Picone, MD |
|
|
|
Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study Read more. |
Mary Ann Picone, MD |
|
|
|
An Open-Label Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Relapsing Remitting Multiple Sclerosis Who Have Had A Suboptimal Response To An Adequate Course Of Disease-Modifying Treatment Read more. |
Mary Ann Picone, MD |
|
|
|
A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) Read more. |
Mary Ann Picone, MD |
|
|
|
A Phase Iii, Multicentre, Randomized, Parallel-Group, Double Blinded, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis Read more. |
Mary Ann Picone, MD |
|
|
|
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a Read more. |
Mary Ann Picone, MD |
|
|